3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT

Timothy Iveson,Kathleen A Boyd,Rachel Kerr,José Antonio Robles-Zurita,Mark P Saunders,Andrew Briggs,Jim Cassidy,Niels Henrik Hollander,Josep Tabernero,Andrew Haydon,Bengt Glimelius,Andrea Harkin,Karen Allan,John McQueen,Sarah Pearson,Ashita Waterston,Louise Medley,Charles Wilson,Richard J. Ellis,Sharadah Essapen,A.S. Dhadda,Mark Harrison,Stephen Falk,Sherif Raouf,Charlotte Rees,Rene K Olesen,David Propper,John Bridgewater,A. Azzabi,David Farrugia,Andrew I. Webb,David Cunningham,Tamas Hickish,Andrew Weaver,Simon Gollins,Harpreet Wasan,James Paul

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT

2019

Background: Oxaliplatin and fluoropyrimidine chemotherapy administered over 6 months is the standard adjuvant regimen for patients with high-risk stage II or III colorectal cancer. However, the reg ...

Keywords:

Oxaliplatin
Regimen
Medicine
Adjuvant
Randomized controlled trial
Capecitabine
Oncology
Chemotherapy
Internal medicine
Colorectal cancer
Intensive care medicine
Fluorouracil

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations